Trial Profile
Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab (Avastin) in Women With Advanced Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 02 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
- 02 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
- 03 Feb 2009 Planned end date changed from 1 Jul 2008 to 1 May 2009, based on information from ClinicalTrials.gov.